Real-world external validation of the Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors in patients with solid tumors
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Purpose The Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors are widely used but were independently evaluated mainly in melanoma. We assessed their prognostic performance in a real-world pan-tumor cohort and explored alternative cutoffs. Methods This retrospective single-center study included adults with solid tumors treated with PD-1/PD-L1 inhibitors for at least 6 weeks, classified as having primary, secondary, or no resistance per the 2020 SITC definitions. Overall survival (OS) was analyzed using Kaplan–Meier methods and multivariable Cox regression, and the threshold separating primary from secondary resistance was varied from 3 to 24 months. Results Of 595 patients (49% non-small cell lung cancer), 294 (49.4%) had primary resistance, 125 (21.0%) secondary resistance, and 176 (29.6%) no resistance. At a median follow-up of 27.7 months, median OS was 28.5 months with primary resistance, 80.3 months with secondary resistance, and not reached without resistance (log-rank p < 0.0001). In multivariable analysis (n = 398), primary resistance (adjusted hazard ratio [aHR] 6.99, 95% CI 3.58–13.6) and secondary resistance (aHR 2.15, 95% CI 1.06–4.35) were associated with higher mortality; estimates were consistent without performance status (n = 568). A 3-month threshold yielded a concordance statistic of 0.777 versus 0.769 at 6 months; longer thresholds progressively reduced discrimination. Conclusion SITC-defined resistance categories stratified OS in this real-world pan-tumor cohort. A shorter threshold did not meaningfully improve discrimination, supporting retention of the 6-month cutoff. Because categories are assigned after treatment initiation, landmark-based and prospective validation is warranted.
Source: Research Square
Institution: American University of Beirut Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236336014
